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What is the key question?  
Do greater improvements of lung function with long-acting beta agonist/long-acting muscarinic antagonist 
(LABA/LAMA) combinations translate into better clinical benefits compared with monotherapies in stable COPD 
patients?  
What is the bottom line? 
The combination therapy was the most effective strategy in improving lung function, quality of life, symptom 
scores, and moderate-to-severe exacerbation rates and had similar effects on safety outcomes and severe 
exacerbations as compared with monotherapies.  
Why read on? 
Our systematic review summarizes the efficacy and safety of LABA/LAMA combination therapy in patients with 
moderate-to-severe COPD and describes the limitations of the current data.  
 
ABSTRACT 
Background: The place of long-acting beta agonist/long-acting muscarinic antagonist (LABA/LAMA) combinations 
in stable COPD patients is not well defined. The purpose of this study was to systematically review the efficacy and 
safety of LABA/LAMA combinations.  
Methods: Several databases and manufacturers’ website were searched for relevant clinical trials. Randomized 
control trials, at least 12 weeks duration, comparing a LABA/LAMA combination with placebo and/or monotherapy 
were included. The data were pooled using a network as well as a traditional direct comparison meta-analysis. 
Results: Twenty three trials with a total of 27,172 patients were included in the analysis. LABA/LAMA 
combinations were associated with a greater improvement in lung function, St. George's Respiratory 
Questionnaire (SGRQ) score, and Transitional Dyspnea (TDI) Index than monotherapies. LABA/LAMA combinations 
were associated with a significantly greater proportion of SGRQ and TDI responders than monotherapies (odds 
ratio (OR) 1.23 [95% credible interval (CrI) 1.06-1.39], OR 1.34 [95% CrI 1.19-1.50] vs. LABAs and OR 1.24 [95% CrI 
1.11-1.36], OR 1.31 [95% CrI 1.18-1.46] vs. LAMAs respectively) and fewer moderate-to-severe exacerbations 
compared with LABAs (hazard ratio (HR) 0.82 [95% CrI 0.73-0.93]), but not when compared with LAMAs (HR 0.92 
[95% CrI 0.84-1.00]). There were no statistically significant differences associated with LABA/LAMA combinations 
compared with monotherapies in safety outcomes as well as in severe exacerbations.  
Conclusion: The combination therapy was the most effective strategy in improving lung function, quality of life, 
symptom scores, and moderate-to-severe exacerbation rates and had similar effects on safety outcomes and 
severe exacerbations as compared with monotherapies.  
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Introduction 
Chronic Obstructive Pulmonary Disease (COPD) will likely become the third leading cause of death by 2030 
according to World Health Organization and continues to be a major cause of disability and rising health care costs 
worldwide.[1] The total cost of COPD in 2010 was $49.9 billion, including health care expenditures of $29.5 billion 
in direct health care costs, $8.0 billion in indirect morbidity costs, and $12.4 billion in indirect mortality costs in the 
United States.[2] These costs were the highest among common lung diseases.  
Current guidelines developed by Global Initiative for COPD (GOLD) recommend a maintenance therapy either with 
a long-acting muscarinic antagonist (LAMA) or a long-acting beta agonist (LABA) in symptomatic patients with 
moderate or more severe COPD.[3] When patients are not adequately controlled with a single long-acting 
bronchodilator, combining a LAMA with a LABA may be beneficial.[4]  
European and Japanese regulatory agencies recently approved a once-daily fixed-dose combination of indacaterol 
and glycopyrronium as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. 
A fixed-dose combination of umeclidinium/vilanterol was approved in the United States and Canada for 
maintenance treatment of COPD.[5] Although LABA/LAMA combination therapies were superior to monotherapies 
with regard to lung function improvement, it is less clear that the surplus of bronchodilation by combination 
therapy would translate into better clinical outcomes such as better quality of life and fewer exacerbations.[6, 7] 
The purpose of this study was to systematically review the efficacy and safety of LABA/LAMA combinations in 
COPD from randomized controlled trials with a network meta-analysis as well as with a traditional direct 
comparison meta-analysis. When no clinical trials exist that directly compare all relevant treatment options, 
indirect comparisons can be made by comparing the relative effects of treatments against a common comparator 
or combining a variety of comparisons that taken together from one or more chains linking the treatments of 
interest (variously referred to as a multiple treatment comparison or network meta-analysis (NMA)).[8]  
 
Methods 
Identification of trials and data extraction 
We identified all relevant clinical trials which evaluated clinical efficacies and safety of a LABA/LAMA combination 
in stable COPD patients without an acute or recent exacerbation. Two authors (YO, STS) independently searched 
the Ovid Medline database for studies published from 1946 to May 21, 2015 using the MeSH headings and 
keywords: randomized controlled trial AND Pulmonary Disease, Chronic Obstructive AND aclidinium, 
glycopyrronium, or tiotropium AND formoterol, indacaterol, olodaterol, salmeterol, or vilanterol OR QVA149. In 
addition, we searched Scopus, CINAHL, and the internet including the online trial registries of manufacturers of 
the above mentioned fixed-dose LABA/LAMA products. Bibliographies of all selected articles and review articles 
which included information on a LABA/LAMA combination in COPD were also reviewed for other relevant articles. 
We included any randomized clinical trial, published or unpublished, evaluating COPD patients with a LABA/LAMA 
combination. Randomized control trials had to be of at least 12 weeks duration. A control intervention had to 
include a placebo, a LABA, or a LAMA. We chose change from baseline (CFB) in trough forced expiratory volume in 
1 second (FEV1) in liter, Transitional Dyspnea Index (TDI), CFB in St. George's Respiratory Questionnaire (SGRQ), a 
proportion of SGRQ and TDI responders (defined as a subject with an improvement of at least four units in SGRQ 
total score or one unit in TDI score),[9] COPD exacerbations, mortality, total serious adverse events (SAEs), cardiac 
SAEs, and dropouts due to adverse event, as the outcome assessment criteria for the purpose of our meta-analysis. 
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Two authors (YO, STS) independently screened studies by title and abstract to evaluate whether a trial met the 
inclusion criteria. We extracted data on COPD exacerbations as moderate and severe. Moderate was generally 
defined as “worsening respiratory status which required treatment with systemic corticosteroids and/or 
antibiotics” and severe as “rapid deterioration which required hospitalization.” Data were abstracted on study 
design, study size, population, severity of illness, and the impact of a LABA/LAMA combination on the end points 
of interest. The risk of bias was assessed with the following items: (1) adequacy of sequence generation, (2) 
allocation concealment, (3) blinding of participants and investigators, (4) blinding of outcome assessment, (5) 
incomplete outcome data, (6) selective outcome reporting, and other bias.[10] Disagreements regarding values or 
analyses were resolved by discussion.   
Statistical analysis 
The primary analyses were NMAs using a Bayesian Markov chain Monte Carlo (MCMC) method and fitted in 
WinBUGS version 1.4.3(Medical Research Council Biostatistics Unit, Cambridge, UK) using code adapted from Dias 
et al, which correctly accounts for correlations in trials with more than two arms.[11] In a Bayesian analysis, a prior 
distribution of a parameter is the probability distribution that represents uncertainty about the parameter before 
the current data are examined. Current data and assumptions concerning how they were generated are 
summarized in the likelihood. Combining the prior distribution and the likelihood functions leads to the posterior 
distribution of the parameter which is used for inference. This distribution will be summarized by its median and 
95% credible interval (CrI). Crls are the Bayesian equivalent of classical confidence intervals, but they are 
interpreted as defining the probability (usually 95%) that the relative treatment effects lie between its bounds.  
NMA estimates the comparative efficacy between all treatments, including those that have not been directly 
compared by including all relevant evidence (direct and indirect), and provide the most flexible approach to 
indirect comparison modeling. For the analyses in WinBUGS, inference was based on 100,000 iterations of MCMC 
with an initial burn-in period of 50,000 iterations.[12]  
A data structure table was constructed to choose an optimal model for each outcome (Table S1 in Online 
Supplement). Model selection and its rationale are summarized in the Table S2 in Online Supplement. Each pair of 
treatments was compared by estimating an odds ratio (OR) or hazard ratio (HR) for a dichotomous outcome and a 
difference in mean or median for a continuous outcome. Treatment baselines and effects were given vague 
normal priors with mean 0 and variance 10,000 and between-trials standard deviations (SDs) were given uniform 
distribution with lower bound 0 and upper bound 5.  The upper bound of 5 was thought to be sufficiently large for 
outcomes on a log scale. The posterior distribution was examined to ensure it was sufficiently different from the 
prior and that the prior was therefore not having undue influence on the resulting posterior. 
 The probability that each intervention arm was associated with being the most efficacious was calculated by 
counting the proportion of iterations of the Markov chain in which each intervention arm had the highest HR, OR, 
or mean difference (MD). The surface under the cumulative ranking (SUCRA), which is a simple numerical 
summary of these probabilities, was also calculated. The SUCRA would be 100% when a treatment is certain to be 
the best and 0% when a treatment is certain to be the worst.[13] 
Assessment of model fit was based on comparison of residual deviance to the number of unconstrained data 
points, and between-study SD. We compared fixed and random effects models using the Deviance Information 
Criterion (DIC), a measure of model fit that penalizes model complexity. The model with lower values on the DIC 
was preferred, with differences of three or more units considered meaningful.[14] If two models had a similar DIC, 
a fixed-effects model was preferred unless there was heterogeneity in the pairwise comparison, in which case a 
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random-effects model was used. Inconsistency was assessed by comparing the model fit and between-study 
heterogeneity from the NMA models with those from an unrelated effects (inconsistency) model.[15] 
The presence of heterogeneity was assessed by comparing a between-trials SD to the size of the relative 
treatment effects, on log-scale for OR and HR. If the between-trials SD approximates the size of treatment effect, 
heterogeneity is likely very high so that results from a future trial could include zero or even harmful effects. 
Heterogeneity was further explored by fitting covariates (i.e., FEV1 at baseline, treatment duration (a minimum of 
6 months), publication status (published vs. unpublished) and smoking status) in a meta-regression analysis.[16] A 
subgroup interaction model was used for the treatment duration and a continuous covariate model was used for 
the rest of covariates.  
We conducted traditional pairwise meta-analyses, considering only direct evidence comparing the combination 
therapy with monotherapies or placebo using the same outcome variables. For the pairwise meta-analysis, we 
tested heterogeneity between trials with I2 statistic with I2 >50% indicating significant heterogeneity. A random 
effects model (DerSimonian-Laird) was used if significant heterogeneity was detected. A fixed-effects model was 
used otherwise. Haldane correction was applied by adding 0.5 to each count when a data set contained zero in 
any cell to make a calculation possible for the main effect or variance.[17] Results from our network meta-analysis 
were qualitatively compared with direct pairwise estimates. The data analysis was performed using meta-analysis 
software (StatsDirect 2.7.8, StatsDirect Ltd, Cheshire UK).  
Sample size calculations and power analyses were conducted for clinically relevant outcomes such as SGRQ and 
TDI responders and COPD exacerbations with a method described by Thorlund and Mills.[18] A required sample 
size was calculated by applying a mean event rate of the comparator arm from the included trials, a type I error of 
5%, and a power of 90%, expecting to detect an additional 20% relative efficacy with the combination arm. 
Heterogeneity was estimated from I2 index of a head-to-head comparison and used for correcting the sample sizes. 
 
RESULTS 
Study Selection 
The electronic database searches identified 112 citations. Ninety seven studies were excluded on abstract review. 
The remaining 15 studies were reviewed for further details. Additional 5 studies were excluded for various reasons 
as shown in Figure 1. Further search on manufactures’ website and internet identified 10 additional studies 
including 3 unpublished studies. We included 23 trials from 20 reports with a total of 27,172 randomized 
patients.[19-38] The study and patient characteristics are presented in Table 1. 
 
Study, year 
No. of 
patients† 
Duration of 
treatment 
(weeks) 
Treatment comparisons 
Mean 
age 
Male % 
Current 
smoker % 
Baseline 
FEV1 % § 
Baseline FEV1 
(L) ≠ 
Buhl 2015 [19] 5162 52 
TIO/OLO 5/5 mcg   
TIO/OLO 2.5/5 mcg   
TIO 5 mcg 
TIO 2.5 mcg 
OLO 5 mcg 
64.0 73 37 50.0 1.17 
Celli 2014 [20] 1489 24 
UMEC/VI 125/25 mcg   
UMEC 125 mcg  
VI 25 mcg  
Placebo 
62.9 65 52 48.2 1.28 
Decramer 2014a [21] 843 24 UMEC/VI 125/25 mcg  62.9 69 51 47.7 1.31 
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UMEC/VI 62.5/25 mcg 
VI 25 mcg  
TIO 18 mcg  
Decramer 2014b [21] 869 24 
UMEC/VI 125/25 mcg 
UMEC/VI 62.5/25 mcg 
UMEC 125 mcg 
TIO 18 mcg 
64.6 68 45 47.1 1.16 
D’Urzo 2014 [22] 1669 24 
ACL/FM 400/12 mcg 
ACL/FM 400/6 mcg 
ACL 400 mcg 
FM 12 mcg 
Placebo 
63.9 53 52 53.5 1.36 
Donohue 2014 [31] 562 52 
UMEC/VI 125/25 mcg 
UMEC 125 mcg 
Placebo 
61.3 67 63 54.7 1.49  
Maleki-Yazdi 2014 
[23] 
905 24 
UMEC/VI 62.5/25 mcg 
TIO 18 mcg 
62.3 68 57 46.3 1.41 § 
Singh 2014 [24] 1729 24 
ACL/FM 400/12 mcg 
ACL/FM 400/6 mcg 
ACL 400 mcg 
FM 12 mcg 
Placebo 
63.2 68 47 54.3 1.41 
Vincken 2014 [25] 447 12 
IND/Glyco 110/50 mcg  
IND 150 mcg  
63.6 81 42 54.9 1.46  
ZuWallack 2014* 
(ANHELTO 1 & 2) 
[26] 
2267 12 
TIO/OLO 18/5 mcg   
TIO 18 mcg 
64.3 52 49 53.7 1.25 
Bateman 2013 [27] 2135 26 
IND/Glyco 110/50 mcg  
IND 150 mcg  
Glyco 50 mcg  
TIO 18 mcg  
Placebo 
63.9 75 40 55.2 1.30  
Dahl 2013 [28] 338 52 
IND/Glyco 110/50 mcg  
Placebo 
62.6 77 45 57.4 1.45  
Donohue 2013 [29] 1532 24 
UMEC/VI 62.5/25 mcg 
UMEC 62.5 mcg  
VI 25 mcg  
Placebo 
63.1 71 50 47.4  1.23 
Wedzicha 2013 [30] 2205 64 
IND/Glyco 110/50 mcg  
Glyco 50 mcg 
TIO 18 mcg  
63.3 75 38 37.2 0.90  
DB2114417 2012 
[32] 
641 12 
UMEC/VI 125/25 mcg 
UMEC/VI 62.5/25 mcg 
VI 25 mcg  
UMEC 125 mcg 
UMEC 62.5 mcg 
Placebo 
61.6 56 63 NR 1.44  
DB2114418 2012 
[33] 
554 12 
UMEC/VI 125/25 mcg   
UMEC/VI 62.5/25 mcg 
VI 25 mcg  
UMEC 125 mcg  
UMEC 62.5 mcg  
Placebo 
62.6 55 61 NR 1.32 
Mahler 2012a [34] 1131 12 
TIO 18 mcg /IND 150 mcg  
TIO 18 mcg  
63.7 69 38 48.6 1.15 
Mahler 2012b [34] 1142 12 
TIO 18 mcg /IND 150 mcg  
TIO 18 mcg  
63 66 40 48.6 1.14 
Novartis A1301 2012 
[35] 
158 52 
IND/Glyco 110/50 mcg  
TIO 18 mcg  
69.3 96 NR NR 1.33 ¶ 
Tashkin 2009 [36] 243 12 
TIO 18 mcg /FM 12 mcg  
TIO 18 mcg  
63.9 66 47 NR NR 
Vogelmeier 2008 
[37] 
847 24 
TIO 18 mcg /FM 10 mcg   
FM 10 mcg   
TIO 18 mcg  
Placebo 
62.6 78 NR 51 1.5 
Aaron 2007 [38] 304 52 
TIO 18 mcg /SAL 50 mcg  
TIO 18 mcg  
67.9 56 26 41.7 1.01 
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Table 1. Study characteristics of included trials.  ACL = aclidinium; FEV1= forced expiratory volume in 1 second; 
FM=formoterol; Glyco= glycopyrronium; IND= indacaterol; NR= not reported; OLO= olodaterol; SAL=salmeterol; 
TIO= tiotropium; UMEC= umeclidinium; VI=vilanterol † Number of patients included in this analysis § post-
bronchodilator  ≠ pre-bronchodilator  ¶ at week 3 * includes 2 trials making a total of 23 trials.  
 
Formoterol, indacaterol, olodaterol, salmeterol, and vilanterol were grouped as LABA and aclidinium, 
glycopyrronium, umeclidinium, and tiotropium were grouped as LAMA. The mean age ranged from 61.3 to 69.3 
years. The proportion of male patients and current smokers ranged from 52% to 96% and 26% to 63%. The mean 
baseline FEV1 ranged from 0.90 to 1.5 liters.  FEV1 percent predicted ranged from 37.2% to 57.4 %. The network 
of treatments is displayed in Figure 2. The treatments formed a closed network, which was amenable to a network 
meta-analysis. 
Methodological quality of included studies 
Generally, the risk of bias in the included studies was deemed moderate to low. Allocation concealment was 
appropriate in 16 studies, and unclear in 3 studies. All trials presented intention-to-treat analyses except for two 
trials which excluded two patients out of 1134 and 1137 patients who did not receive the study treatment.[26] 
Nineteen studies were double blinded (Table S3 in Online Supplement). In the opinion of the authors, there were 
no studies that clearly should have been excluded from the analysis because of differences in baseline 
characteristics or poor quality.  
Consistency assessment (Similarity of participants, interventions and trial methodology)  
All trials were consistent in their key inclusion and exclusion criteria (Table S4 in Online Supplement). All studies 
recruited patient with aged > 35-40 years with a diagnosis of COPD in accordance with American Thoracic Society-
European Respiratory Society or GOLD guidelines, at least 10 pack year of smoking history, and moderate or 
severe disease with FEV1 of ranging 30 to 70 percent of predicted. Patients with asthma, and other respiratory or 
cardiovascular disease were excluded in all trials. The concomitant use of a fixed dose of inhaled corticosteroids 
(ICS) was allowed in most studies, prohibited in two studies [26, 38], and unclear in one study [35] which was 
addressed in a sensitivity analysis. A recent COPD exacerbation within a month of study entry was usually excluded 
from the study. Baseline characteristics of studied patients were similar in all included studies (Table 1) as well as 
in class pair-wise comparisons (e.g. LABA vs. combination, LAMA vs. placebo. Table S5 in Online Supplement). 
Baseline FEV1 was somehow lower in the combination vs. LAMA comparison, but summary baseline 
characteristics were comparable across pair-wise comparisons between classes. Trial duration varied across 
studies which was addressed by including only data relevant to the time points specified or by modelling the data 
as hazards with the binominal-cloglog model which allows for the different follow-up time. In general, 
characteristics of participants, interventions and trial methodology were fairly comparable in all studies and across 
pairwise comparisons, and therefore we found nothing to suggest that the consistency assumption may not hold. 
Network meta-analysis  
The clinical trials were synthesized with a network meta-analysis. The individual study results are presented in 
Table S6-8 in Online Supplement. The autocorrelation plots showed that throughout the iterative process the 
autocorrelation was satisfactorily reduced to a nominal amount and the Brooks-Gelman-Rubin plots showed that 
the model had converged satisfactorily.[39] When examining outcome measures, a fixed-effects model showed 
largely similar DIC values and results as a random-effects model. A random-effects model was chosen in all 
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outcomes according to our prespecified selection criteria except for CFB in SGQR at 3 months, TDI, proportion of 
TDI responders, severe exacerbations, mortality, and total SAEs. The between study heterogeneity and DICs were 
similar between the NMA and inconsistency models suggesting no evidence of inconsistency in the network, 
although this should be interpreted with caution as there may not be sufficient power to detect inconsistency. 
Ranking results of each outcome are presented in Table 2. 
 
Probability of being the best 
therapy 
SUCRA value Median ranking [95% CrI] 
Treatment Change from baseline in FEV1 (L) - 3 months 
Placebo 0% 0%  4[4-4] 
LABA 0% 33.4%  3[3-3] 
LAMA 0% 66.6%  2[2-2] 
LABA/LAMA 100% 100%  1[1-1] 
Treatment Change from baseline in FEV1 (L) - 6 months 
Placebo 0% 0%  4[4-4] 
LABA 0% 33.6%  3[3-3] 
LAMA 0% 66.4%  2[2-2] 
LABA/LAMA 100% 100% 1[1-1] 
 Change from baseline in FEV1 (L) - 12 months 
Placebo 0.1% 0.5% 3[3-3] 
LABA N/A N/A N/A 
LAMA 2.1% 50.7%  2[2-2] 
LABA/LAMA 97.7% 98.8%  1[1-1] 
 Change from baseline in SGRQ – 3 months 
Placebo 0% 0%  4[4-4] 
LABA 0% 49.0%  2[2-3] 
LAMA 0% 51.0%  3[2-3] 
LAMA/LABA 100% 100%  1[1-1] 
 Change from baseline in SGRQ – 6 months 
Placebo 0% 0.1% 4[4-4] 
LABA 0.6% 52.2% 2[2-3] 
LAMA 0.1% 47.9% 3[2-3] 
LAMA/LABA 99.2% 99.7% 1[1-2] 
 SGRQ responder†– 6 months 
Placebo 0% 0.4% 4[4-4] 
LABA 0.4% 67.2% 2[2-3] 
LAMA 0% 36.8% 3[2-3] 
LAMA/LABA 99.5% 95.6% 1[1-2] 
 Transitional Dyspnea Index – 3 months 
Placebo 0% 0%  4[4-4] 
LABA 0% 55.7%  2[2-3] 
LAMA 0% 44.3%  3[2-3] 
LABA/LAMA 99.9% 100%  1[1-1] 
 Transitional Dyspnea Index – 6 months 
Placebo 0% 0%  4[4-4] 
LABA 0% 43.0%  3[2-3] 
LAMA 0% 57.0%  2[2-3] 
LABA/LAMA 99.4% 100%  1[1-1] 
 TDI responder*– 6 months 
Placebo 0% 0%  4[4-4] 
LABA 0% 44.2%  3[2-3] 
LAMA 0.1% 55.8%  2[2-3] 
LABA/LAMA 99.9% 100%  1[1-1] 
 Moderate-to-severe exacerbations 
Placebo 0% 2.6%  4[4-4] 
LABA 0.2% 34.3%  3[2-3] 
LAMA 2.9% 66.5%  2[1-3] 
LAMA/LABA 97.0% 99.0%  1[1-2] 
 Severe exacerbations 
Placebo 4.6% 10.2% 4[1-4] 
LABA 37.4% 66.0% 2[1-4] 
LAMA 7.5% 44.8% 3[1-4] 
LAMA/LABA 50.5% 79.0% 1[1-3] 
 Mortality 
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Placebo 84.8% 91.4% 1[1-4] 
LABA 7.6% 41.3% 3[1-4] 
LAMA 0.6% 14.5% 4[2-4] 
LAMA/LABA 7.1% 52.7% 3[1-4] 
 Total serious adverse events 
Placebo 62.7% 76.4% 1[1-4] 
LABA 6.6% 23.6% 4[1-4] 
LAMA 26.0% 64.7% 2[1-4] 
LAMA/LABA 4.7% 35.2% 3[1-4] 
 Cardiac serious adverse events 
Placebo 89.6% 94.7% 1[1-3] 
LABA 2.1% 22.3% 4[2-4] 
LAMA 1.6% 28.3% 3[2-4] 
LAMA/LABA 6.7% 54.6% 2[1-4] 
 Dropout due to adverse event 
Placebo 22.7% 42.8% 3[1-4] 
LABA 11.7% 29.6% 3[1-4] 
LAMA 42.0% 70.0% 2[1-4] 
LAMA/LABA 23.5% 57.6% 2[1-4] 
Table 2. Probability of best therapy, SUCRA values and ranking of therapy. *defined as a subject with a TDI 
score of one unit or more. †defined as a subject with a SGRQ score of 4 units below baseline or lower. CFB=change 
from baseline; CrI= credible interval; FEV1= forced expiratory volume in 1 second; LABA= long-acting beta-
agonist; LAMA=long-acting muscarinic antagonist; N/A= not applicable; SGRQ=St. George's Respiratory 
Questionnaire; SUCRA= surface under the cumulative ranking curve; TDI= Transitional Dyspnea Index. 
 
Forced expiratory volume in 1 second (FEV1) 
Trough FEV1 data were available in 13, 12 and 4 trials at 3, 6, and 12 months (n=12224, 16065, and 4836 
respectively). Improvement in trough FEV1 to the end of the trials was greater with LABA/LAMA combinations 
than with placebo, LABAs or LAMAs at all time points. LABA/LAMA combinations were ranked first [95% CrI 1-1] at 
all time points, with a mean improvement over placebo of 201ml [95% CrI 172, 230] to 243ml [95% CrI 139, 351]. 
LAMAs and LABAs were ranked second and third with the MDs of 64ml [95%CrI 51, 78] to 73ml [95% CrI 43, 149] 
and 95ml [95% CrI 71, 117] to 104ml [95% CrI 84, 126] compared with LABA/LAMA combinations. Class differences 
did not appear significantly different at 3, 6 and 12 months, except for LABAs at 12 months at which time point 
data were not available. (Fig. 3)  Wider 95% CrIs were observed at 12 months as the number of included studies 
decreased.   
Health related quality of life and symptom scales (SGRQ and TDI scores and responders) 
The data for CFB in SGRQ and TDI were available in 9 and  6 trials at 3 months and 9 and 8 trials at 6 months (n= 
12042, 7315, 12716, and 14568 respectively). The data for SGRQ and TDI responders at 6 months were available in 
12 and 7 trials (n=18,536 and 9,045 respectively). The combination therapy was ranked highest, followed by LABAs 
and LAMAs in all SGRQ outcomes. The efficacy of combination therapy in CFB in SGRQ was less prominent at 6 
months as compared with 3 months, especially with LABAs (MD -4.6 [95% CrI -5.9, -3.3], -2.3 [95% CrI -3.3, -1.3], 
and -2.3 [95% CrI -2.9, -1.7] for placebo, LABAs and LAMAs respectively at 3 months and -4.1 (95% CrI -5.9, -2.3), -
1.1 (95% CrI -2.5, 0.4), and -1.6 (95% CrI -2.8, -0.5) at 6 months Fig. 4A). Although the MD and its 95% CrI between 
combination therapy and monotherapies did not reach the minimum clinically important difference of 4 points in 
SGRQ score, LAMA/LABA combinations were associated with a significantly greater proportion of SGRQ 
responders compared with LAMAs and LABAs (OR 1.23 [95% CrI 1.06, 1.39] and1.24 [95% CrI 1.11, 1.36] 
respectively Fig. 5).  
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As for TDI, the combination therapy was ranked highest, followed by LABAs or LAMAs.  The combination therapy 
yielded a significant improvement in TDI score compared with placebo, LABAs and LAMAs at 3 months (MD 1.21 
[95% CrI 0.95, 1.48], 0.37 [95% CrI 0.16, 0.57], and 0.41 [95% CrI 0.23, 0.59] respectively). The class differences 
remained constant and statistically significant at 6 months (Fig. 4B). Although the MD and its 95% CrI between 
combination therapy and monotherapies did not reach the minimum clinically important difference of 1 point in 
TDI, LAMA/LABA combinations were associated with a significantly greater proportion of TDI responders 
compared with LAMAs and LABAs (OR 1.34 [95% CrI 1.16, 1.56] and 1.30 [95% CrI 1.13, 1.48] respectively Fig. 5). 
The 95% CrIs of ranking suggested that only combination therapy could be ranked first in all SGRQ and TDI 
outcomes (Table 2). 
COPD exacerbations 
COPD exacerbation data were available in 16 trials (n=18,224) for moderate-to-severe exacerbations and in 19 
trials (n=25,401) for severe exacerbations. LABA/LAMA combinations were ranked first and second for the 
prevention of moderate-to-severe and severe exacerbations with a probability of being the best therapy of 97.0% 
and 30.2% respectively. The combination therapy was associated with significantly fewer moderate-to-severe 
exacerbations compared with placebo and LABAs (HR 0.66[95% CrI 0.57, 0.77], 0.82 [95% CrI 0.73, 0.93] 
respectively), but not when compared with LAMAs (HR 0.92 [95%CrI 0.84, 1.00]). LAMAs had a median rank of two 
in preventing moderate-to-severe exacerbations and the 95% CrI suggested that they could also be ranked first, 
second, or third (median ranking 2 [95%CrI 1-3]).  There were no significant differences in severe exacerbations 
associated with LABA/LAMA combinations compared with placebo, LABAs, or LAMAs and there was a large degree 
of overlap in ranking (Fig. 6 and Table 2). 
Adverse events 
The results of safety outcomes are presented in Table 3. There were no significant differences in mortality, total 
SAEs, or dropouts due to adverse event among all comparators (Table 3).  
 
Mortality FE 
HR (95%CrI) 
Total SAEs FE 
HR (95%CrI) 
Cardiac SAEs RE 
HR (95%CrI) 
Dropouts due to AE 
RE HR (95%CrI) 
No. of studies 15 20 16 16 
No. of patients 24,041 27,172 25,913 23,529 
vs. placebo 1.95 (0.73, 7.71) 1.10 (0.89, 1.38) 1.65 (0.81, 3.35) 0.95 (0.71, 1.28) 
vs. LABA 0.99 (0.61, 1.66) 0.96 (0.84, 1.10) 0.82 (0.46, 1.35) 0.92 (0.72, 1.19) 
vs. LAMA 0.87 (0.64, 1.16) 1.04 (0.95, 1.14) 0.87 (0.59, 1.27) 1.03 (0.84, 1.26) 
Table 3. Summary effects of LABA/LAMA combinations versus comparators on adverse events. Note: 
Abbreviations: AE=adverse event; CrI=credible interval; FE= fixed-effects; HR= hazard ratio; LABA= long-acting 
beta-agonist; LAMA= long-acting muscarinic antagonist; RE= random-effects; SAE=serious adverse event. 
 
There was considerable overlap in credible intervals and rankings.  Any arm including placebo could be ranked as 
the best therapy in all safety outcomes except for LAMAs in mortality and cardiac SAEs and LABAs in cardiac SAEs. 
Placebo was ranked highest in mortality, total SAEs, and cardiac SAEs. LABA/LAMA combinations were ranked 
second in mortality, cardiac SAEs, and dropouts due to adverse event, but again, there was a large degree of 
overlap (Table 3).Assessment of consistency and exploration of heterogeneity 
The between-trials SDs were relatively large compared with the relative treatment effects in severe exacerbations, 
mortality, total SAEs, cardiac SAEs and dropouts due to adverse event (Table S9 in Online Supplement). The meta-
regression adjustment for the proportion of active smokers, FEV1 at baseline, study duration (a minimum of 6 
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months), and publication status (published vs. unpublished) did not alter the main findings. Between-trials 
heterogeneity was either unchanged, increased, or only slightly reduced with the introduction of those covariates. 
Comparisons between network and direct pairwise meta-analyses were similar in magnitude and direction of 
effect estimates, with the exception of the combination vs. LAMA comparison in moderate-to-severe 
exacerbations and the combination vs. LAMA comparison in dropouts due to adverse event. However, these 
inconsistencies did not alter the main findings (Table S10 in Online Supplement).  Two studies included a randomly 
assigned group that received tiotropium as an open-label treatment.[30, 37] The concomitant use of ICS was 
prohibited in two studies[26, 38] and unclear in one study.[30] We performed a sensitivity analysis excluding these 
studies and the results were essentially unchanged. 
Power analyses and sample size calculations 
The heterogeneity-corrected effective total sample size for the SGRQ and TDI responders and moderate-to-severe 
exacerbations was greater than the required sample size to detect additional 20% relative efficacy with a power of 
90% (Table S11 in Online Supplement).  Statistical power for combination therapy vs. comparators were 95% or 
greater in those outcomes.  On the other hand, the effective total sample size for severe exacerbations was 
substantially smaller than the required sample size except for the combination therapy vs. LAMA comparison.  
Statistical power estimates for the combination therapy vs. placebo, LABA and LAMA comparisons were 29.8%, 
55.5%, and 93.5% respectively in severe exacerbations.  
 
DISCUSSION 
Our systematic review of the currently available randomized trials of LABA/LAMA combinations for stable COPD 
demonstrated that LABA/LAMA combinations yielded a greater improvement in trough FEV1, and SGRQ and TDI 
scores than monotherapies. The ranking statistics demonstrated that combination therapy was the most effective 
strategy in improving lung function, quality of life and symptom scores as well as in reducing moderate-to-severe 
exacerbations. The combination therapy was associated with a significantly greater proportion of SGRQ and TDI 
responders than monotherapies. The combination therapy was ranked highest in reducing moderate-to-severe 
exacerbations and was associated with significantly fewer exacerbations than LABAs, but not when compared with 
LAMAs. LAMAs could also be ranked first in reducing moderate-to-severe exacerbations.  There were no 
statistically significant differences among all comparators in severe exacerbations or safety outcomes, including 
mortality, total SAEs, cardiac SAEs, and dropouts due to adverse event. The sample size analysis suggested that the 
analyses for severe exacerbations were underpowered except for the combination vs. LAMA comparison. The 
sample size for SGRQ and TDI responders and moderate-to-severe exacerbations appeared adequate.  
The results of our analysis are in line with a previous meta-analysis which demonstrated tiotropium/LABA 
combinations were associated with a small increase in lung function and a statistically significant improvement in 
quality of life compared with tiotropium alone. Improvement in other secondary outcomes, such as COPD 
exacerbations and SAEs was similar between both groups.[40] It is not surprising that dual therapies were not 
associated with significantly fewer exacerbations compared with LAMAs in the current analysis given that the 
concomitant use of LABA did not enhance the efficacy of LAMAs in reducing COPD exacerbations in a recent meta-
regression analysis. [41] A similar phenomenon was observed among short-acting bronchodilators. Only 
ipratropium containing arms had reduced COPD exacerbations and adding albuterol to ipratropium did not reduce 
COPD exacerbations compared with ipratropium alone.[42] It was speculated that alterations in mucus production, 
rheology by glands, or mucus clearance in small airways were primarily responsible for COPD exacerbations which 
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were favorably affected by anticholinergics rather than by beta-2 agonists. The above notion is further supported 
by the current analysis with the strength of the NMA, which is the correct inclusion of multi-arm trials, of which 
this network had many, including several studies comparing all four interventions.  
It is important to note the limitations of our study. First, heterogeneity was observed in both pairwise and network 
meta-analyses. None of the trial-level covariates we assessed explained the heterogeneity. Patient and study 
characteristics of the included studies were relatively homogenous, but between-trial comparisons are known to 
be vulnerable to ecologic bias.[13] The subgroup analysis to assess biases by systematic differences between 
studies was also compromised due to limited information. For example, the proportion of current smokers and 
baseline pre-bronchodilator FEV1 values were not available in a few studies included in this analysis (Table 1). 
Individual patient data would be necessary to avoid ecological bias and gain a much greater statistical power to 
detect a true covariate effect. Other effect modifies including body mass index, Medical Research Council dyspnea 
score, exercise capacity (six-minute walk distance), presence of emphysema on chest computed tomography and 
cardiac comorbidities may have influenced the study results. Second, as with all meta-analyses, we are limited by 
the amount of evidence that is published, consequently some of the analyses may fail to detect a true treatment 
effect. Our sample size calculation suggested that the assessment of severe exacerbations was significantly 
underpowered except for the combination vs. LAMA comparison (Table S11 in the Online Supplement). Future 
studies enrolling patients at much higher risk for COPD exacerbations would be helpful to increase the statistical 
power and shed further light on the efficacy of LABA/LAMA combinations on severe exacerbations.   An imbalance 
in study and patient characteristics across trials cannot be completely excluded as with all meta-analyses because 
patients are not randomized to different trials and randomization would not hold across the set of trials used for 
the analysis. The results were unchanged when adjusted for study level covariates, but the risk of residual 
confounding bias from unknown or unmeasured effect modifiers cannot be excluded.[43] However, it is unlikely 
that the results are substantially biased given the consistency of results between network and direct comparison 
meta-analyses and the purpose of our evidence synthesis is to provide an estimate, and its uncertainty, based on 
the current available evidence. Third, the data included in the network meta-analysis was extracted from 
randomized trials and the results may not be generalizable to all patients with COPD. Forth, a cost analysis was not 
conducted. Future studies, especially ones that compares LABA/LAMA, LABA/ICS, and LABA/LAMA/ICS 
combinations are necessary to determine the most cost-effective treatment option.  
 
CONCLUSIONS 
 Our network analysis demonstrated that the combination therapy was the most effective strategy in improving 
lung function, quality of life, symptom scores, and moderate-to-severe exacerbation rates. The combination 
therapy was associated with fewer moderate-to-severe exacerbations compared with LABAs, but not when 
compared with LAMAs. The combination therapy had similar effects on safety outcomes and severe exacerbations 
as compared with monotherapies. Future studies including patients with a more severe form of COPD and 
comparing LABA/LAMA, LABA/ICS and LABA/LAMA/ICS combinations would help health care practitioners and 
societies to better position the place of LABA/LAMA combinations in the armamentarium of COPD therapies.     
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exacerbation outcomes. YO produced the figures and all authors contributed to the writing of the manuscript. 
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FIGURE LEGENDS 
Figure 1. Flow of study selection.  
Figure 2. Diagram displaying the network of 4 arms involved in the Bayesian analysis. The links between nodes 
are used to indicate a direct comparison between pairs of treatments. The numbers shown along the link lines 
indicate the number of trials comparing pairs of treatments head-to-head.  Abbreviations: LABA= long-acting beta-
agonist; LAMA= long-acting muscarinic antagonist.  
Figure 3. Summary effects of LABA/LAMA combination versus comparators on changes in trough FEV1 at 3, 6, 
and 12 months. Note: Mean difference in liters (95% credible interval) Abbreviations: LABA= long-acting beta-
agonist; LAMA= long-acting muscarinic antagonist.  
Figure 4. Summary effects of LABA/LAMA combination versus comparators on changes in (A) St. George's 
Respiratory Questionnaire and (B) Transition Dyspnea Index at 3 and 6 months. Note: Mean difference (95% 
credible interval). Abbreviations: LABA= long-acting beta-agonist; LAMA= long-acting muscarinic antagonist. 
Figure 5. Summary effects of LABA/LAMA combination versus comparators on proportion of SGRQ and TDI 
responders at 6 months. Note: Odds ratio (95% credible interval). A responder was defined as a subject with an 
improvement of at least four units in SGRQ total score or one unit in TDI score. Abbreviations: LABA= long-acting 
beta-agonist; LAMA= long-acting muscarinic antagonist; SGRQ=St. George's Respiratory Questionnaire; 
TDI=Transition Dyspnea Index. 
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Figure 6. Summary effects of LABA/LAMA combination versus comparators on COPD exacerbations. Note: 
Hazard ratio (95% credible interval). Abbreviations: LABA= long-acting beta-agonist; LAMA= long-acting muscarinic 
antagonist. 
 
 
  
16 
 
 
Figure 1 Flow of study selection. 
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Figure 2. Diagram displaying the network of 4 arms involved in the Bayesian analysis.  
The links between nodes are used to indicate a direct comparison between pairs of treatments. The numbers 
shown along the link lines indicate the number of trials comparing pairs of treatments head-to-head.  
Abbreviations: LABA= long-acting beta-agonist; LAMA= long-acting muscarinic antagonist. 
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Figure 3. Summary effects of LABA/LAMA combination versus comparators on changes in trough FEV1 at 3, 6, 
and 12 months. Note: Difference in change from baseline in liters (95% credible interval) Abbreviations: LABA= 
long-acting beta-agonist; LAMA= long-acting muscarinic antagonist. 
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Figure 4. Summary effects of LABA/LAMA combination versus compactors on changes in (A) St. George's 
Respiratory Questionnaire and (B) Transition Dyspnea Index at 3 and 6 months. Note: Difference in change from 
baseline (95% credible interval) Abbreviations:LABA= long-acting beta-agonist; LAMA= long-acting muscarinic 
antagonist. 
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Figure 5. Summary effects of LABA/LAMA combination versus comparators on proportion of SGRQ and TDI 
responders at 6 months.  Note: Odds ratio (95% credible interval). A responder was defined as a subject with an 
improvement of at least four units in SGRQ total score or one unit in TDI score. Abbreviations: LABA= long-
acting beta-agonist; LAMA= long-acting muscarinic antagonist; SGRQ=St. George's Respiratory Questionnaire; 
TDI=Transition Dyspnea Index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
 
Figure 6. Summary effects of LABA/LAMA combination versus comparators on COPD exacerbations. Note: 
Hazard ratio (95% credible interval). Abbreviations: LABA= long-acting beta-agonist; LAMA= long-acting 
muscarinic antagonist. 
 
 
